Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXNNASDAQ:BCLINASDAQ:BTAIOTCMKTS:GPLB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$8.08-0.1%$7.67$6.51▼$13.27$8.56M1.6293,413 shs745 shsBCLIBrainstorm Cell Therapeutics$1.11+3.1%$1.09$0.72▼$8.09$8.84M0.35357,518 shs271,319 shsBTAIBioXcel Therapeutics$1.45+5.8%$1.63$1.17▼$27.20$8.78M0.081.20 million shs88,215 shsGPLBGreen Planet Bioengineering$0.11$0.17$0.00▼$0.70$2.20M3.07955 shsN/AA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics+3.72%-5.61%+1.01%+3.05%-11.11%BCLIBrainstorm Cell Therapeutics-2.70%0.00%-14.29%-31.65%-85.60%BTAIBioXcel Therapeutics+3.79%-1.44%-23.03%-49.82%-94.93%GPLBGreen Planet Bioengineering0.00%0.00%0.00%-83.58%+21,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics2.5189 of 5 stars3.55.00.00.02.20.80.0BCLIBrainstorm Cell Therapeutics4.4213 of 5 stars3.55.00.04.72.60.80.6BTAIBioXcel Therapeutics4.03 of 5 stars3.33.00.04.52.01.70.6GPLBGreen Planet BioengineeringN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 3.00Buy$30.00271.52% UpsideBCLIBrainstorm Cell Therapeutics 3.00Buy$30.002,593.97% UpsideBTAIBioXcel Therapeutics 2.67Moderate Buy$42.602,837.93% UpsideGPLBGreen Planet Bioengineering 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GPLB, ADXN, BCLI, and BTAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/19/2025BTAIBioXcel TherapeuticsRODMAN&RENSHAWSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/19/2025BTAIBioXcel TherapeuticsRodman & RenshawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$404.10K21.18N/AN/A$1.20 per share6.73BCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.20) per shareN/ABTAIBioXcel Therapeutics$1.85M4.74N/AN/A($30.21) per share-0.05GPLBGreen Planet BioengineeringN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics-$11.76M-$0.34N/A∞N/A850.30%-112.43%-77.95%6/9/2025 (Estimated)BCLIBrainstorm Cell Therapeutics-$17.19M-$3.36N/AN/AN/AN/AN/A-528.56%8/13/2025 (Estimated)BTAIBioXcel Therapeutics-$179.05M-$13.55N/AN/AN/A-3,119.33%N/A-105.04%8/5/2025 (Estimated)GPLBGreen Planet BioengineeringN/AN/A0.00∞N/AN/AN/AN/AN/ALatest GPLB, ADXN, BCLI, and BTAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/9/2025Q1 2025ADXNAddex Therapeutics-$1.4197N/AN/AN/AN/AN/A5/15/2025Q1 2025BCLIBrainstorm Cell Therapeutics-$0.38-$0.45-$0.07-$0.45N/AN/A5/12/2025Q1 2025BTAIBioXcel Therapeutics-$2.72-$1.50+$1.22-$1.50$0.35 million$0.17 million3/27/2025Q4 2024BTAIBioXcel Therapeutics-$4.36-$3.57+$0.79-$3.57$0.72 million$0.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ABTAIBioXcel TherapeuticsN/AN/AN/AN/AN/AGPLBGreen Planet BioengineeringN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A4.594.59BCLIBrainstorm Cell TherapeuticsN/A0.050.05BTAIBioXcel TherapeuticsN/A1.871.81GPLBGreen Planet BioengineeringN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%BCLIBrainstorm Cell Therapeutics14.33%BTAIBioXcel Therapeutics30.68%GPLBGreen Planet BioengineeringN/AInsider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%BCLIBrainstorm Cell Therapeutics11.15%BTAIBioXcel Therapeutics21.20%GPLBGreen Planet BioengineeringN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.06 million901,000Not OptionableBCLIBrainstorm Cell Therapeutics407.94 million5.32 millionOptionableBTAIBioXcel Therapeutics906.06 million2.44 millionOptionableGPLBGreen Planet Bioengineering120.01 millionN/ANot OptionableGPLB, ADXN, BCLI, and BTAI HeadlinesRecent News About These CompaniesGreen Planet Bio Engineering changes auditorsMay 17, 2025 | uk.investing.comGreen Planet Bioengineering Co., Ltd. (GPLB)February 11, 2025 | ca.finance.yahoo.comScientists Create Plant-Animal Hybrids That PhotosynthesizeNovember 5, 2024 | newsweek.comUrban PlanetMay 7, 2024 | cambridge.orgGreen New DealMay 6, 2024 | gp.orgThe Green Planet Badge QuizMarch 27, 2024 | bbc.co.ukGreen Planet Bioengineering Co Ltd GPLBFebruary 22, 2024 | morningstar.comMake your own Green Planet inspired seed ballsDecember 9, 2023 | bbc.co.ukGreen Planet Bioengineering Co. Ltd.June 28, 2023 | wsj.comHuman PlanetMay 24, 2023 | bbc.co.uk7 Possible Causes of Green PoopMay 21, 2023 | healthline.comWhat Is Green Chemistry?April 11, 2023 | acs.orgGreen Planet Bioengineering Co Ltd (GPLB)January 17, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGPLB, ADXN, BCLI, and BTAI Company DescriptionsAddex Therapeutics NASDAQ:ADXN$8.07 -0.01 (-0.06%) As of 12:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Brainstorm Cell Therapeutics NASDAQ:BCLI$1.11 +0.03 (+3.11%) As of 01:15 PM EasternBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.BioXcel Therapeutics NASDAQ:BTAI$1.45 +0.08 (+5.84%) As of 01:21 PM EasternBioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Green Planet Bioengineering OTCMKTS:GPLB$0.11 0.00 (0.00%) As of 06/3/2025Green Planet Bioengineering Co. Ltd. operates as a shell company, with the purpose of acquisition and merging with an existing business operation. The company was founded on October 30, 2006 and is headquartered in Aventura, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Analog Devices' Cyclical Recovery Story Has Just Begun Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
